Susan G. Kreissman
Experienced in Beta Thalassemia
Experienced in Beta Thalassemia

Overview

Susan Kreissman is a Pediatrics provider in Durham, North Carolina. Dr. Kreissman has been practicing medicine for over 41 years and is rated as an Experienced provider by MediFind in the treatment of Beta Thalassemia. Her top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Hepatoblastoma, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 30 peer reviewed articles and participating in 48 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
New York University Mount Sinai School Of Medicine, 1985.0
Specialties
Pediatrics
Licenses
Pediatric Hematology-Oncology in NC
Board Certifications
American Board Of Pediatrics, Pediatric Hematology-Oncology
Fellowships
Pediatric Hematology-Oncology, Children's Hospital, Dana Farber Cancer Center (Massachusetts)
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

Duke Children's Health Center Hematology/Oncology Clinic
2301 Erwin Rd, Durham, NC 27710
Other Locations
Duke Children's Hematology/Oncology Creekstone
4709 Creekstone Dr, Durham, NC 27703
Duke Children's Hospital & Health Center
2301 Erwin Rd, Durham, NC 27710

Additional Areas of Focus

Dr. Kreissman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


48 Clinical Trials

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
View 46 Less Clinical Trials
Similar Doctors
Nirmish R. Shah
Experienced in Beta Thalassemia
Hematology | Pediatrics
Experienced in Beta Thalassemia
Hematology | Pediatrics

Duke Adult Comprehensive Sickle Cell Center - Clinic 2N

40 Duke Medicine Cir, 
Durham, NC 
 (9.9 miles away)
Experience:
26+ years
Languages Spoken:
English
Offers Telehealth

As director of Duke’s sickle cell transition program, my practice and research focuses on treating children and adults with sickle cell disease. When I work with children, I try to focus on teaching them about their condition and how to transition successfully to living with the disease as an adult. For all patients, I focus on providing the medical, social and psychological support they need to remain healthy. My research aims to increase engagement of sickle cell patients with their own care using mobile technology. Through the use of applications, we’re hoping to help patients, specifically children, better manage their symptoms and medications. Outside of work, I have a strong interest in art. In fact, one of my undergraduate majors was biological illustration. I enjoy drawing plants, animals and people. I’ve recently started getting back into this hobby. Dr. Shah is rated as a Distinguished provider by MediFind in the treatment of Beta Thalassemia. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Transplant.

Experienced in Beta Thalassemia
Pediatrics | Hematology Oncology
Experienced in Beta Thalassemia
Pediatrics | Hematology Oncology
2100 Erwin Rd, 
Durham, NC 
 (10.0 miles away)
Languages Spoken:
English
Accepting New Patients

Shelly Burgett is a Pediatrics specialist and a Hematologist Oncology provider in Durham, North Carolina. Dr. Burgett is rated as an Experienced provider by MediFind in the treatment of Beta Thalassemia. Her top areas of expertise are Sickle Cell Disease, Beta Thalassemia, Hemophilic Arthropathy, and Hemophilia A. Dr. Burgett is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kreissman's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile